Chloe Ramirez
The AstraZeneca and Johnson & Johnson vaccines are both viral vector vaccines that use a harmless version of a cold virus as a vector to give our cells the instructions they need to make the coronavirus's spike protein. The immune system then recognizes the protein and makes antibodies, allowing us to fight off the virus if exposed in the future. However, the carriers are different kinds of adenoviruses, with Johnson & Johnson using a human adenovirus and AstraZeneca using a chimpanzee adenovirus. Both vaccines have faced negative media coverage and public perception issues due to concerns over blood clotting issues, with scientists exploring a possible link between the two.
| Characteristics | Values |
|---|---|
| Vaccine Technology | Same |
| Vaccine Type | Both are adenovirus-based |
| Number of Doses | Johnson & Johnson: 1 |
| AstraZeneca: 2 | |
| Side Effects | Johnson & Johnson: 9% of participants reported symptoms of fever, and 0.2% reported a Grade 3 fever |
| AstraZeneca: Similar side effects | |
| Blood Clot Risk | Johnson & Johnson: Rare |
| AstraZeneca: Rare | |
| Efficacy | Johnson & Johnson: 72% effective at preventing all COVID-19 |
| AstraZeneca: 65% effective | |
| Effectiveness Against Serious Illness | Johnson & Johnson: 86% effective |
| AstraZeneca: 85% effective | |
| Effectiveness Against Death | Johnson & Johnson: 100% effective |
| AstraZeneca: N/A |
Explore related products
What You'll Learn
AstraZeneca and J&J vaccines are both adenovirus-based
The AstraZeneca and Johnson & Johnson (J&J) vaccines are both viral vector vaccines that use adenoviruses to carry the genetic information of the COVID-19 virus to human cells. Adenoviruses are a common type of virus that typically causes mild cold symptoms when they infect someone. The vaccines use a harmless version of the adenovirus as a vector to deliver the instructions that our cells need to make the coronavirus's spike protein. This spike protein triggers the body's immune system to start producing antibodies to COVID-19, which then allows us to fight off the virus if we are exposed to it in the future.
The J&J vaccine uses a human adenovirus, or a cold virus, to create its vaccine, while the AstraZeneca vaccine uses a chimpanzee adenovirus. Despite these differences, both vaccines use the same underlying technology, which differs from the mRNA vaccines developed by Pfizer-BioNTech and Moderna. The mRNA vaccines use synthetic mRNA packaged in a fat coating, which is dumped directly into the cell when the vaccine is injected into the arm muscle. The mRNA is then translated into protein to make the antibody.
The AstraZeneca and J&J vaccines are also similar in terms of their side effects. In clinical trials, about 9% of participants in the J&J vaccine trials reported symptoms of fever, while 0.2% reported a Grade 3 fever (between 102 and 104 degrees Fahrenheit). For the AstraZeneca vaccine, side effects such as fever and muscle aches were similar to those observed in the J&J vaccine trials. Importantly, patients who received either vaccine and subsequently contracted COVID-19 were not seriously ill or hospitalized for it.
Both the AstraZeneca and J&J vaccines have faced challenges due to perceptions of their efficacy compared to the mRNA vaccines. The J&J and AstraZeneca vaccines posted overall efficacy rates in the 65-66% range, while the Pfizer and Moderna vaccines had efficacy rates well over 90%. However, it is important to note that direct comparison studies of the vaccines are lacking, and the J&J and AstraZeneca vaccines were tested more recently when new, more contagious variants were circulating. As a result, the J&J and AstraZeneca vaccines may be more effective against these newer variants than the efficacy rates from the initial trials suggest.
Despite their similarities, the AstraZeneca and J&J vaccines have some key differences. The J&J vaccine is a single-dose vaccine, making it logistically easier to administer than the two-dose AstraZeneca vaccine. Additionally, the J&J vaccine does not require freezer storage, making it easier to ship and store than the mRNA vaccines, which must be shipped and stored at below-freezing temperatures.
The Skin's Truth: Unveiling the Facts
You may want to see also
Explore related products
J&J's vaccine is a single-dose vaccine
The Johnson & Johnson COVID-19 vaccine is a single-dose vaccine, as announced by the company in February 2021. The vaccine was authorised by the U.S. Food and Drug Administration (FDA) for emergency use, making it the first single-shot vaccine in the fight against the global pandemic. The Janssen COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, was found to be 85% effective in preventing severe disease and showed protection against COVID-19-related hospitalisation and death, beginning 28 days after vaccination.
The Johnson & Johnson vaccine is adenovirus-based, similar to the AstraZeneca vaccine. However, the carriers are different kinds of adenoviruses, which are a common type of virus that typically causes mild cold symptoms when it infects someone. The Johnson & Johnson vaccine can be stored at room temperature for 12 hours when the vial hasn't been punctured. After the first dose is withdrawn, the vial can be stored in a fridge for six hours or at room temperature for two hours.
While the Johnson & Johnson vaccine is a single-dose vaccine, a booster shot is recommended at least two months after the initial dose for everyone 18 and older. This is due to the vaccine's lower effectiveness compared to mRNA vaccines, and the booster can help increase its effectiveness. The side effects from the booster shot are similar to those of the initial dose, including pain at the injection site, headache, fatigue, muscle aches, fever, and chills.
The Johnson & Johnson vaccine faced some challenges due to negative media coverage and perception issues, similar to the AstraZeneca vaccine. However, the company worked to communicate the safety and effectiveness of the vaccine, emphasising its 85% effectiveness against serious illness and 100% effectiveness in preventing death. The vaccine was studied in nearly 44,000 people across various regions, providing data on its protection against COVID-19-related hospitalisation and death.
Antibodies: How They Attack Pathogens
You may want to see also
Explore related products
AstraZeneca's vaccine has faced negative media coverage in Europe
The AstraZeneca vaccine has faced negative media coverage in Europe due to concerns about side effects and blood clots. Several countries, including Austria, initially halted the use of certain batches of the vaccine, while others like Belgium, Poland, the Czech Republic, and Ukraine continued administering it. This decision caused intense divisions in Europe, with Poland's vaccination head, Michal Dworczyk, attributing the pause to "panic caused by media coverage of alleged complications".
The negative media coverage of the AstraZeneca vaccine in Europe has had a detrimental impact on vaccine acceptance, not just within Europe but also internationally. A study from the UK found that some individuals questioned the vaccine due to its rapid development, with concerns about safety and negative experiences. This is further exacerbated by confusing data reports and a lack of transparency, resulting in a mishmash of authorizations worldwide.
AstraZeneca's vaccine was developed in partnership with Oxford University, and they have faced criticism for their role in the confusing data reports and lack of transparency. However, an AstraZeneca spokesperson emphasized that their vaccine is effective across all adult age groups, especially older adults, and that their focus remains on ensuring broad and equitable global access to help overcome the pandemic.
The similarities between the AstraZeneca and Johnson & Johnson vaccines have led to comparisons and concerns about blood clot issues. Scientists are exploring a possible link, and while there is no conclusive evidence, there is a growing consensus in the scientific community. Experts emphasize that even if a link is established, the risk of developing a blood clot is exceedingly rare and lower than the probability of being struck by lightning.
The Johnson & Johnson vaccine rollout in the US has benefited from straightforward communications, with CEO Alex Gorsky emphasizing its safety and effectiveness. In contrast, AstraZeneca faced a patchwork of age-group approvals and conflicting government statements, further complicating its perception.
Hep B Vaccine: When Did It Start Being Given at Birth?
You may want to see also
Explore related products
Both vaccines have been linked to rare blood clotting issues
The AstraZeneca and Johnson & Johnson vaccines are made in a similar way, both being adenovirus-based. However, the carriers are different kinds of adenoviruses. Both vaccines have been linked to rare blood clotting issues, with scientists exploring a possible link between the two. A prevailing theory is that viral vector vaccines somehow trigger an abnormal immune response, leading to blood clots. Scientists in Germany identified a specific antibody in many people who developed clots after receiving the AstraZeneca vaccine, and U.S. researchers subsequently identified the same antibody in individuals who developed similar clots after receiving the Johnson & Johnson vaccine.
While the Johnson & Johnson vaccine has been linked to a rare and potentially life-threatening form of blood clotting called thrombosis with thrombocytopenia syndrome (TTS), the risk is exceedingly low. The AstraZeneca vaccine has also been linked to rare blood clots, with scientists in Germany identifying a specific antibody present in many people who developed clots after receiving the vaccine. This same antibody was subsequently identified in individuals who developed clots after receiving the Johnson & Johnson vaccine.
The similarities between the blood clotting issues associated with the two vaccines have scientists exploring a possible link. Dr. William Schaffner, an infectious disease physician at Vanderbilt University, noted that while the carriers are different kinds of adenoviruses, there is a growing consensus in the scientific community that the vaccines trigger an antibody response that activates platelets, leading to clots. However, experts have cautioned that even if there is a link, the current evidence suggests that the risk of developing a blood clot after receiving either vaccine is very low.
The Johnson & Johnson vaccine is a single-dose vaccine, while the AstraZeneca vaccine requires two doses. Both vaccines have been shown to be effective in preventing serious illness and death from COVID-19. The Johnson & Johnson vaccine was found to be 86% effective in preventing severe cases of COVID-19, while the AstraZeneca vaccine has been approved by the World Health Organization (WHO) and is being used throughout much of the world to bolster the global immunization effort.
Plague Vaccine: A Historical Perspective
You may want to see also
Explore related products
The AstraZeneca vaccine is marketed as Vaxzevria
Vaxzevria has been estimated to have prevented 50 million COVID-19 cases, about five million hospitalizations, and saved over a million lives worldwide. As of May 15, 2022, about 69 million doses of Vaxzevria have been administered to adults in the EU/EEA. The World Health Organization (WHO) recommends an interval of 8 to 12 weeks between doses for optimal efficacy.
AstraZeneca withdrew its marketing authorizations for the vaccine from the European market in March 2024 and worldwide by May 2024. The European Medicines Agency (EMA) authorized Vaxzevria in February 2021. On March 26, 2021, the EMA posted 'Vaxzevria' as the new name for the COVID-19 Vaccine AstraZeneca.
The Johnson & Johnson and AstraZeneca vaccines are similar in that they are both adenovirus-based. However, they use different types of adenoviruses as carriers. Scientists have explored a possible link between the two vaccines and rare blood clot issues. While a specific antibody was identified in people who developed clots after receiving either vaccine, the risk of developing a blood clot is considered exceedingly low.
Bacterial Meningitis Vaccine: Who Should Avoid It?
You may want to see also
Frequently asked questions
Both vaccines are adenovirus-based vector vaccines, which means they use a harmless adenovirus vector to carry the COVID-19 virus' DNA to human cells. The adenovirus then delivers the DNA to the cell, which produces a COVID-19 spike protein. This spike protein triggers the body's immune system to create antibodies to fight the COVID-19 virus.
The AstraZeneca and Johnson & Johnson vaccines have different carriers of the adenovirus. The Johnson & Johnson vaccine is also known as the Janssen vaccine, and it is delivered using a different method. While both vaccines have similar side effects, the AstraZeneca vaccine has a higher occurrence of adverse symptoms.
Scientists have explored a possible link between the two vaccines and rare blood clot issues. However, it is important to note that the risk of developing a blood clot is exceedingly low, and there is no definitive evidence of a causal relationship. Public health officials and the companies themselves have worked to address negative media coverage and perception issues surrounding the vaccines.
